The Saga of Hydroxychloroquine and COVID-19: A Cautionary Tale

Authors

Neil W. Schluger, New York Medical CollegeFollow

DOI

10.7326/M20-5041

Journal Title

Annals of Internal Medicine

First Page

662

Last Page

663

Document Type

Editorial

Publication Date

10-20-2020

Department

Medicine

Keywords

Antimalarials, Betacoronavirus, COVID-19, Coronavirus Infections, Humans, Hydroxychloroquine, Pandemics, Pneumonia, Viral, SARS-CoV-2

Disciplines

Infectious Disease | Medicinal and Pharmaceutical Chemistry | Medicine and Health Sciences

Abstract

In their article, Skipper and colleagues report the results of trial of hydroxychloroquine for patients presenting with nonsevere COVID-19. The editorialists discuss the findings and the need to examine carefully not only what we know about hydroxychloroquine and COVID-19 but also how we learned it, disseminated it, and put it into practice.

Recommended Citation

Schluger, N. W. (2020). The Saga of Hydroxychloroquine and COVID-19: A Cautionary Tale. Annals of Internal Medicine, 173 (8), 662-663. https://doi.org/10.7326/M20-5041